286.27
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Cencora Inc stock is traded at $286.27, with a volume of 2.13M.
It is up +1.82% in the last 24 hours and up +7.04% over the past month.
Cencora is one of three domestic leading pharmaceutical wholesalers. It sources and distributes branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospital networks, and healthcare providers. It and McKesson and Cardinal Health constitute over 90% of the us pharmaceutical wholesale industry. Cencora also provides commercialization services for manufacturers of pharmaceuticals and medical devices, global specialty drug logistics (World Courier), and animal health product distribution (MWI Animal Health). Cencora expanded its international presence in 2021 by purchasing Alliance Healthcare, one of the leading drug wholesalers in Europe.
See More
Previous Close:
$281.16
Open:
$281.81
24h Volume:
2.13M
Relative Volume:
1.26
Market Cap:
$55.12B
Revenue:
$303.19B
Net Income/Loss:
$1.40B
P/E Ratio:
40.72
EPS:
7.03
Net Cash Flow:
$-638.10M
1W Performance:
+0.61%
1M Performance:
+7.04%
6M Performance:
+22.25%
1Y Performance:
+20.87%
Cencora Inc Stock (COR) Company Profile
Name
Cencora Inc
Sector
Industry
Phone
610-727-7000
Address
1 WEST FIRST AVENUE, CONSHOHOCKEN
Compare COR with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
COR
Cencora Inc
|
286.27 | 55.12B | 303.19B | 1.40B | -638.10M | 7.03 |
![]()
MCK
Mckesson Corporation
|
695.17 | 87.12B | 344.58B | 2.83B | 1.63B | 21.84 |
![]()
CAH
Cardinal Health Inc
|
133.69 | 32.56B | 222.16B | 1.31B | -486.00M | 5.36 |
![]()
HSIC
Henry Schein Inc
|
64.54 | 8.04B | 12.50B | 314.00M | 421.00M | 2.44 |
![]()
OMI
Owens Minor Inc
|
6.47 | 513.74M | 10.42B | -38.77M | 323.54M | -0.51 |
Cencora Inc Stock (COR) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Dec-04-24 | Resumed | Mizuho | Outperform |
Sep-18-24 | Downgrade | BofA Securities | Buy → Neutral |
Feb-26-24 | Initiated | Leerink Partners | Outperform |
Jan-03-24 | Initiated | Barclays | Overweight |
Dec-14-23 | Initiated | Wells Fargo | Equal Weight |
Mar-31-23 | Initiated | Citigroup | Buy |
Jan-31-23 | Resumed | Evercore ISI | Outperform |
Oct-11-22 | Upgrade | BofA Securities | Neutral → Buy |
Aug-22-22 | Resumed | Morgan Stanley | Equal-Weight |
Jul-11-22 | Downgrade | Evercore ISI | Outperform → In-line |
Jun-07-22 | Upgrade | Deutsche Bank | Hold → Buy |
May-26-22 | Upgrade | Barclays | Equal Weight → Overweight |
Apr-12-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
Apr-01-22 | Resumed | Credit Suisse | Outperform |
Mar-12-21 | Resumed | Evercore ISI | In-line |
Feb-04-21 | Upgrade | Evercore ISI | In-line → Outperform |
Feb-02-21 | Upgrade | Cowen | Market Perform → Outperform |
Jan-06-21 | Upgrade | BofA Securities | Underperform → Neutral |
Jan-06-21 | Upgrade | Credit Suisse | Neutral → Outperform |
Dec-10-20 | Downgrade | Wells Fargo | Equal Weight → Underweight |
Dec-03-20 | Initiated | Mizuho | Neutral |
Aug-06-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
Jul-15-20 | Initiated | Barclays | Underweight |
Jun-15-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
Apr-23-20 | Resumed | Credit Suisse | Outperform |
Apr-16-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
Apr-13-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
Apr-01-20 | Upgrade | JP Morgan | Neutral → Overweight |
Mar-17-20 | Upgrade | Citigroup | Neutral → Buy |
Feb-11-20 | Downgrade | BofA/Merrill | Buy → Underperform |
Feb-07-20 | Upgrade | Robert W. Baird | Neutral → Outperform |
Sep-12-19 | Initiated | Deutsche Bank | Hold |
Jul-10-19 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
Apr-11-19 | Initiated | Guggenheim | Buy |
Apr-10-19 | Downgrade | BofA/Merrill | Buy → Underperform |
Apr-10-19 | Downgrade | Evercore ISI | Outperform → In-line |
Feb-11-19 | Downgrade | JP Morgan | Neutral → Underweight |
Jan-17-19 | Initiated | UBS | Buy |
Dec-10-18 | Downgrade | Jefferies | Buy → Hold |
Oct-26-18 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
Sep-20-18 | Initiated | Berenberg | Buy |
Jul-17-18 | Resumed | Stifel | Hold |
Apr-09-18 | Initiated | MoffettNathanson | Buy |
Mar-12-18 | Upgrade | KeyBanc Capital Mkts | Sector Weight → Overweight |
Mar-12-18 | Upgrade | Raymond James | Mkt Perform → Outperform |
Sep-25-17 | Initiated | JP Morgan | Neutral |
Sep-22-17 | Initiated | William Blair | Outperform |
View All
Cencora Inc Stock (COR) Latest News
Healthcare Cold Chain Logistics Market Report 2025-2035 | High Costs of Cold Storage and Transportation Pose Challenges for Healthcare Logistics - GlobeNewswire Inc.
Is Cencora, Inc. (COR) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Lobbying Update: $60,000 of CENCORA INC. lobbying was just disclosed - Nasdaq
Will Cencora (COR) Beat Estimates Again in Its Next Earnings Report? - Yahoo Finance
Why Cencora (COR) is a Top Momentum Stock for the Long-Term - Yahoo Finance
Jim Cramer: Cencora (COR) Is a “Must-Own” Drug Middleman – Even If It Should Be Digitized Away - Insider Monkey
TD Cowen Adjusts Price Target on Cencora to $335 From $288, Keeps Buy Rating - marketscreener.com
Baird Adjusts Price Target on Cencora to $314 From $308, Keeps Outperform Rating - marketscreener.com
Jim Cramer is Bullish on These 10 Stocks - Insider Monkey
Morgan Stanley Adjusts Cencora Price Target to $288 From $263, Maintains Equal Weight Rating - MarketScreener
Morgan Stanley Increases Price Target for Cencora (COR) to $288 - GuruFocus
Jim Cramer Likes Cencora (COR) “Middlemen Always Work.” - Insider Monkey
Cencora to Announce Q2 Fiscal 2025 Results on May 7 - MSN
Jim Cramer Discussed These 12 Stocks - Insider Monkey
Here's Why You Should Add Cencora Stock to Your Portfolio Now - MSN
Cencora, Inc. (COR): A Bull Case Theory - MSN
Mizuho raises Cencora stock price target to $305, maintains outperform By Investing.com - Investing.com Canada
Evercore ISI Adjusts Price Target on Cencora to $320 From $280, Maintains Outperform Rating - marketscreener.com
Top 3 MedTech Stocks to Weather the Trump Tariff Turbulence - TradingView
Mizuho raises Cencora stock price target to $305, maintains outperform - Investing.com Australia
These 5 S&P 500 Winners Held Strong In Q1 — Can The Rally Continue? - Benzinga
Why We're Not Concerned About Cencora, Inc.'s (NYSE:COR) Share Price - simplywall.st
4 Low-Beta Healthcare Stocks to Beat Trump's Tariff Blues - TradingView
Sellers Rule The Roost Amid Tariff Wars, But This Stock Hits A High - Investor's Business Daily
Has Cencora, Inc. (COR) Outpaced Other Medical Stocks This Year? - Yahoo Finance
Leerink Partners Adjusts Price Target on Cencora to $317 From $301, Maintains Outperform Rating - MarketScreener
Insiders At Cencora Sold US$16m In Stock, Alluding To Potential Weakness - Yahoo Finance
Cencora (COR) is a Top-Ranked Growth Stock: Should You Buy? - Yahoo Finance
Jim Cramer on Cencora (COR): “Smart Moves in the Drug Middleman Game!” - Insider Monkey
Jim Cramer Looked At These 23 Stocks Recently - Insider Monkey
Zacks Industry Outlook Highlights Cencora, Doximity and Pediatrix Medical - Yahoo Finance
Cencora Announces Date and Time for Second Quarter Fiscal 2025 Earnings Release - Business Wire
$290B Revenue Powerhouse Cencora Sets Critical Q2 Earnings Call Date - Stock Titan
Walden Group sale: DHL & Cencora show interest in deal - Trans.INFO
Cencora (COR) is a Top-Ranked Value Stock: Should You Buy? - Yahoo Finance
Cencora, Inc. (COR) Hit a 52 Week High, Can the Run Continue? - Yahoo Finance
AmerisourceBergen stock soars to all-time high of $271.17 By Investing.com - Investing.com South Africa
Cencora executive chairman sells $3.9 million in stock By Investing.com - Investing.com Canada
Cencora EVP Elizabeth Campbell sells $1.1 million in stock By Investing.com - Investing.com South Africa
Cencora EVP Elizabeth Campbell sells $1.1 million in stock - Investing.com
Cencora executive chairman sells $3.9 million in stock - Investing.com
Deutsche Bank Adjusts Cencora Price Target to $285 From $24 - MarketScreener
AmerisourceBergen stock soars to all-time high of $271.17 - Investing.com
Walgreens Boots Alliance, Inc. Reduces Stake in Cencora Inc. - GuruFocus
Logistics Firm Walden Is Said to Draw Interest from DHL, Cencora - MSN
Q4 Earnings Highlights: Cencora (NYSE:COR) Vs The Rest Of The Health Insurance Providers Stocks - The Globe and Mail
Insider Sell: Robert Mauch Sells Shares of Cencora Inc (COR) - GuruFocus
Cencora Inc Stock (COR) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):